Alzheimer's Disease Research Laboratory, Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, 16th St., Charlestown, MA 02129, USA.
FASEB J. 2013 Aug;27(8):3239-48. doi: 10.1096/fj.13-229666. Epub 2013 May 2.
There is a growing body of evidence that soluble oligomeric forms of amyloid β (Aβ) play a critical role in Alzheimer's disease (AD). Despite the importance of soluble Aβ oligomers as a therapeutic target for AD, the dynamic metabolism of these Aβ species in vivo has not been elucidated because of the difficulty in monitoring brain Aβ oligomers in living animals. Here, using a unique large pore-sized membrane microdialysis, we characterized soluble Aβ oligomers in brain interstitial fluid (ISF) of awake, freely moving APP/PS1 transgenic and control WT mice. We could detect high-molecular-weight (HMW) and low-molecular-weight (LMW) Aβ oligomers in the brain ISF of living animals, which increased dramatically in an age-dependent manner (5- to 8-fold increase, 4 vs. 17-18 mo). Notably, HMW Aβ decreased more slowly than other forms of Aβ after acute γ-secretase inhibition [% decrease from the baseline (HMW vs. LMW) was 36.9 vs. 74.1% (Aβ40, P<0.05) and 25.4 vs. 88.0% (Aβ42, P<0.01)], suggesting that HMW Aβ oligomers clear more slowly than other forms from the brain. These data reveal the dynamic metabolism of neurotoxic Aβ oligomers in AD brain and could provide new insights into Aβ-targeted therapies for AD.
越来越多的证据表明,可溶性寡聚体形式的淀粉样β(Aβ)在阿尔茨海默病(AD)中发挥着关键作用。尽管可溶性 Aβ 寡聚物作为 AD 的治疗靶点非常重要,但由于难以在活体动物中监测脑 Aβ 寡聚物,这些 Aβ 物种在体内的动态代谢尚未阐明。在这里,我们使用独特的大孔径膜微透析技术,在清醒、自由活动的 APP/PS1 转基因和对照 WT 小鼠的脑间质液(ISF)中对可溶性 Aβ 寡聚物进行了表征。我们可以在活体动物的脑 ISF 中检测到高分子量(HMW)和低分子量(LMW)Aβ 寡聚物,这些寡聚物随年龄的增长而显著增加(5-8 倍增加,4 岁与 17-18 岁)。值得注意的是,与其他形式的 Aβ 相比,急性 γ-分泌酶抑制后 HMW Aβ 的减少速度较慢(从基线下降的百分比(HMW 与 LMW)为 36.9%与 74.1%(Aβ40,P<0.05)和 25.4%与 88.0%(Aβ42,P<0.01]),表明 HMW Aβ 寡聚物从大脑中的清除速度比其他形式的 Aβ 慢。这些数据揭示了 AD 大脑中神经毒性 Aβ 寡聚物的动态代谢,可为 AD 的 Aβ 靶向治疗提供新的见解。